Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.59 |
| ▸ | GABRD | O14764 | 2/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.59 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.59 |
| ▸ | GABRE | P78334 | 2/20 | 0.59 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.59 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.59 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.59 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9792766 | 0.80 | CYP1A2 (0.58) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL446809 | 0.78 | GABRP (0.70) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18375601 | 0.77 | CYP1A2 (0.59) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL13847385 | 0.77 | CYP1A2 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28556647 | 0.76 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL312500 | 0.75 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1726856 | 0.75 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30705741 | 0.74 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL220538 | 0.74 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19586492 | 0.72 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| EP-3265088-A1 | SREBP BLOCKERS FOR USE IN TREATING LIVER FIBROSIS, ELEVATED CHOLESTEROL AND INSULIN RESISTANCE | Medivation Technologies LLC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3038622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| WO-2015031650-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | CHAKRAVARTY SARVAJIT (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | GABRP 2461/4885GABRD 747/4885GABRA1 2066/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | GABRP 3372/4885GABRD 3990/4885GABRA1 4410/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | GABRP 1194/4885GABRD 3038/4885GABRA1 2775/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | GABRP 3138/4885GABRD 3671/4885GABRA1 2977/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | GABRP 3372/4885GABRD 3990/4885GABRA1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.